<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02643303</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2014-011</org_study_id>
    <nct_id>NCT02643303</nct_id>
  </id_info>
  <brief_title>A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers</brief_title>
  <official_title>A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter Phase 1/2 study of the CTLA-4 antibody, tremelimumab, and&#xD;
      the PD-L1 antibody, durvalumab (MEDI4736), in combination with the tumor microenvironment&#xD;
      (TME) modulator polyICLC, a TLR3 agonist, in subjects with advanced, measurable,&#xD;
      biopsy-accessible cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 28, 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) at 24 weeks</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Analyzed by irRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>up to 15 months</time_frame>
    <description>Adverse events according to CTCAE V4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by objective response rate (ORR)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by progression-free survival (PFS)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Efficacy by overall survival (OS)</measure>
    <time_frame>up to 15 months</time_frame>
    <description>assessed by irRECIST</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Breast Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Merkel Cell Carcinoma</condition>
  <condition>Cutaneous T-Cell Lymphoma</condition>
  <condition>Melanoma</condition>
  <condition>Renal Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Prostate Cancer</condition>
  <condition>Testicular Cancer</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IV Tremelimumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV Durvalumab + IT Tremelimumab + IT/IM polyICLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the recommended combination doses of the triplet dosing regimen has been determined in Cohort 1C, subsequent subjects will be enrolled into Cohort 2 to receive the recommended combination doses of both checkpoint antibodies in combination with polyICLC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poly ICLC</intervention_name>
    <arm_group_label>Phase 1, Cohort 1A</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1B</arm_group_label>
    <arm_group_label>Phase 1, Cohort 1C</arm_group_label>
    <arm_group_label>Phase 2 Cohort</arm_group_label>
    <other_name>Hiltonol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have histologic confirmation of advanced, biopsy-accessible, measurable&#xD;
             cancers of the following histologies:&#xD;
&#xD;
               -  Non-viral-associated head and neck squamous cell carcinoma (HNSCC) or&#xD;
                  HPV-associated HNSCC after failure of prior therapy&#xD;
&#xD;
               -  Locally recurrent or metastatic breast cancer&#xD;
&#xD;
               -  Sarcoma&#xD;
&#xD;
               -  Merkel Cell Carcinoma (MCC)&#xD;
&#xD;
               -  Cutaneous T cell Lymphoma (CTCL)&#xD;
&#xD;
               -  Melanoma after failure of available therapies&#xD;
&#xD;
               -  GU cancers with accessible metastases (e.g., bladder, renal)&#xD;
&#xD;
               -  Any solid tumors with masses that are accessible&#xD;
&#xD;
          2. Subjects with measurable disease, must have at least 2 lesions (1 measurable lesion&#xD;
             and 1 biopsy/injectable lesion, which will not need to be measurable).&#xD;
&#xD;
          3. Any number of prior systemic therapies.&#xD;
&#xD;
          4. ECOG performance status 0-1.&#xD;
&#xD;
          5. Laboratory parameters for vital functions should be in the normal range or not&#xD;
             clinically significant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior treatment with combination CTLA-4 and PD-1/PD-L1 blockade, with the exception of&#xD;
             subjects with melanoma.&#xD;
&#xD;
          2. Participants may not have been treated intratumorally with polyICLC.&#xD;
&#xD;
          3. Subjects with history or evidence upon physical examination of central nervous system&#xD;
             (CNS) disease, including primary brain tumor, seizures not controlled with standard&#xD;
             medical therapy, any active brain metastases, or, within 6 months of the first date of&#xD;
             treatment on this study, history of cerebrovascular accident (CVA, stroke), transient&#xD;
             ischemic attack (TIA) or subarachnoid hemorrhage.&#xD;
&#xD;
          4. Active, suspected or prior documented autoimmune disease, clinically significant&#xD;
             cardiovascular disease or clinically uncontrolled hypertension.&#xD;
&#xD;
          5. History of pneumonitis or interstitial lung disease or any unresolved immune-related&#xD;
             adverse events following prior biological therapy.&#xD;
&#xD;
          6. Other malignancy within 2 years prior to entry into the study, except for those&#xD;
             treated with surgical therapy only (e.g., localized low-grade cervical or prostate&#xD;
             cancers).&#xD;
&#xD;
          7. Subjects with clinical symptoms or signs of gastrointestinal obstruction and/or who&#xD;
             require drainage gastrostomy tube and/or parenteral hydration or nutrition.&#xD;
&#xD;
          8. Known immunodeficiency or HIV, Hepatitis B, or Hepatitis C positivity. Antibody to&#xD;
             Hepatitis B or C without evidence of active infection may be allowed.&#xD;
&#xD;
          9. History of severe allergic reactions to any unknown allergens or any components of the&#xD;
             study drugs.&#xD;
&#xD;
         10. Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding&#xD;
             disorders).&#xD;
&#xD;
         11. History of allogeneic organ transplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L Slingluff, Jr., MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nina Bhardwaj, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Tisch Cancer Institute Ichan School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Tremelimumab</keyword>
  <keyword>PolyICLC</keyword>
  <keyword>Hiltonol</keyword>
  <keyword>Locally Recurrent Breast Cancer</keyword>
  <keyword>Metastatic Melanoma</keyword>
  <keyword>In Situ</keyword>
  <keyword>CTLA-4 Antibody</keyword>
  <keyword>PD-L1 Antibody</keyword>
  <keyword>TLR3 Agonist</keyword>
  <keyword>CTCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Poly ICLC</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

